Curriculum Vitae

Mary Jennifer Abuzzahab
345 N Smith Ave
St Paul, MN 55102

PERSONAL

DATE OF BIRTH: January 31, 1965
BIRTHPLACE: Hastings, Minnesota
MEDICAL LICENSE: 42796, Minnesota
35-06-3583, Ohio
1920-320, Wisconsin

EDUCATION

MEDICAL:

Children's Hospital Medical Center, Cincinnati, Ohio
Pediatric Endocrine Fellowship 1997 - 2000
Columbus Children's Hospital/The Ohio State University, Columbus, Ohio
Pediatric Internship and Residency 1991 - 1994
Chief Resident 1994 - 1995
Eastern Virginia Medical School, Norfolk, Virginia
Medical Doctorate 1987 - 1991

UNDERGRADUATE:

The College of William and Mary, Williamsburg, Virginia
Bachelor of Science in Biology; minor in English 1983 - 1987

BOARD CERTIFICATIONS

Pediatrics	#052535	1994 - Present
Pediatric Endocrinology	#000860	2001 - Present

HOSPITAL AFFILIATIONS

Children's Minnesota, St Paul, MN
Pediatric Endocrinologist 2000 - present
Yukon-Kuskokwim Delta Regional Hospital, Bethel, Alaska
General Pediatrician 1995 - 1997

PROFESSIONAL MEMBERSHIPS

Fellow, American Academy of Pediatrics	1991 - present
Member, The Endocrine Society	1999 - present
Member, Lawson Wilkins Pediatric Endocrine Society	2003 - present
Member, European Society of Paediatric Endocrinology	2020 - present

COMMITTEES AND PROFESSIONAL AFFILIATIONS

2009-2015	Chair, Health Information Management Committee (Children's Minnesota)
2016-2021	Member, PREP Endocrinology Editorial Board
2017-2020	Associate Chief, Medicine (Children's Minnesota)
2018-2020	Faculty, PES Fellows Retreat
2020-Present	Chair, Credentials Committee (Children's Minnesota)
2020-Present	Member, Raymond A. Wood Foundation Scientific and Clinical Advisory Board

PUBLICATIONS

Zydus EX1004
U.S. Patent No. 12,233,106

Bergmann KR, **Abuzzahab MJ**, Perepelista V, Udeogu J, Qiu L, Lammers S, Nickel A, Watson D, Kharbanda A. Improving Emergency Department Care for Children With Medium- and High-Risk Diabetic Ketoacidosis. *Pediatrics*. 2025 Oct 1;156(4).

Phillip M, **Abuzzahab MJ**, Pietropoli A, Ferran JM, Højby M, Kelepouris N, Kotnik P, Polak M, Sävendahl L. Comparative Outcomes of GH Treatment in Pediatric Idiopathic Short Stature and GH Deficiency. *J Endocr Soc.* 2025 Aug 16;9(10).

Nally LM, Sherr JL, Garg SK, Marks BE, Laffel LM, Pihoker C, Accacha SD, Thrasher JR, **Abuzzahab MJ**, Reed JH, Ekhlaspour L, Belapurkar S, Shulman DI, Sunil B, MacLeish SA, Latif K, Forlenza GP, Castorino K, Lal RA, Bode BW, Broyles FE, Carlson AL, Nwosu BU, Shin J, Ma H, Salbato A, Cordero TL, Treminio Y, McVean JJ, Rhinehart AS, Vigersky RA; SUCCEED Study Group. Safety and Glycemic Outcomes of the MiniMed 780G System with a Disposable All-in-One Sensor. *Diabetes Technol Ther*. 2025 Aug 18.

Abuzzahab MJ, Dubern B, Goldstone AP, Haqq AM, Heymsfield SB, Miller JL, Richards J, Wabitsch M, Yanovski JA. Improving the diagnosis of hyperphagia in melanocortin-4 receptor pathway diseases. *Obesity (Silver Spring)*. 2025 Jul;33(7):1217-1231. Epub 2025 Jun 17.

Bergmann KR, Bjornstad P, **Abuzzahab MJ**, Zhong L, Collins-Dippel E, Nickel A, Watson D, Kharbanda A. Multicentre, retrospective cohort study protocol to identify racial and ethnic differences in acute kidney injuries in children and adolescents with diabetic ketoacidosis. *BMJ Open*. 2024 Jun 5;14(6).

Roth CL, Scimia C, Shoemaker AH, Gottschalk M, Miller J, Yuan G, Malhotra S, **Abuzzahab MJ**. Setmelanotide for the treatment of acquired hypothalamic obesity: a phase 2, open-label, multicentre trial. *Lancet Diabetes Endocrinol*. 2024 Jun;12(6):380-389. Epub 2024 Apr 30.

Miller JL, Gevers E, Bridges N, Yanovski JA, Salehi P, Obrynba KS, Felner EI, Bird LM, Shoemaker AH, Angulo M, Butler MG, Stevenson D, Goldstone AP, Wilding J, Lah M, Shaikh MG, Littlejohn E, **Abuzzahab MJ**, Fleischman A, Hirano P, Yen K, Cowen NM, Bhatnagar A; C601/C602 Investigators. Diazoxide choline extended-release tablet in people with Prader-Willi syndrome: results from long-term open-label study. *Obesity (Silver Spring).* 2024 Feb;32(2):252-261.

Savarirayan R, Hoernschemeyer DG, Ljungberg M, Zarate YA, Bacino CA, Bober MB, Legare JM, Högler W, Quattrin T, **Abuzzahab MJ**, Hofman PL, White KK, Ma NS, Schnabel D, Sousa SB, Mao M, Smith A, Chakraborty M, Giwa A, Winding B, Volck B, Shu AD, McDonnell C. Once-weekly TransCon CNP (navepegritide) in children with achondroplasia (ACcomplisH): a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-escalation trial. *EClinicalMedicine*. 2023 Oct 2;65:102258.

Bergmann KR, Boes M, Velden HV, **Abuzzahab MJ**, Watson D. Intravenous fluid bolus volume and resolution of acute kidney injury in children with diabetic ketoacidosis. *Pediatr Emerg Care*. 2023 Feb 1;39(2):67-73.

Miller JL, Gevers E, Bridges N, Yanovski JA, Salehi P, Obrynba KS, Felner EI, Bird LM, Shoemaker AH, Angulo M, Butler MG, Stevenson D, **Abuzzahab J**, Barrett T,

Lah M, Littlejohn E, Mathew V, Cowen NM, Bhatnagar A. Diazoxide choline Extended-Release Tablet in People with Prader-Willi Syndrome: A Double-Blind, Placebo-Controlled Trial. *J Clin Endocrinol Metab*. 2023 Jan 14.

Butler M, Miller B, Romano A, Ross J, **Abuzzahab MJ,** Backeljauw P, Bamba V, Bhangoo A, Mauras N, Geffner M. Genetic conditions of short stature: A review of three classic examples. *Front. Endocrinol.* 2022 October 21;13:1-30.

Bergmann KR, Nickel A, Hall M, Cutler G, **Abuzzahab MJ**, Bretscher B, Lammers S, Watson D, Hester GZ. Association of neighborhood resources and race and ethnicity with readmissions for Diabetic Ketoacidosis at US children's hospitals. *JAMA Netw Open*. 2022 May;5(5):1-14.

Maniatis AK, Nadgir U, Saenger P, Reifschneider KL, **Abuzzahab J**, Deeb L, Fox LA, Woods KA, Song W, Mao M, Chessler SD, Komirenko AS, Shu AD, Casella SJ, Thornton PS. Switching to Weekly Lonapegsomatropin from Daily Somatropin in Children with Growth Hormone Deficiency: The fliGHt Trial. *Horm Res Paediatr*. 2022;95(3):233-243.

Shoemaker AH, Silver HJ, Buchowski M, Slaughter JC, Yanovski JA, Elfers C, Roth CL, **Abuzzahab MJ**. Energy balance in hypothalamic obesity in response to treatment with a once-weekly GLP-1 receptor agonist. *Int J Obes (Lond)*. 2022 Jan 3.

Perez FA, Elfers C, Yanovski JA, Shoemaker AH, **Abuzzahab MJ**, Roth CL. MRI measures of hypothalamic injury are associated with glucagon-like peptide-1 receptor agonist treatment response in people with hypothalamic obesity. *Diabetes Obes Metab*. 2021 Jul;23(7):1532-1541.

Bergmann KR, **Abuzzahab MJ**, Nowak J, Arms J, Cutler G, Christensen E, Finch M, Kharbanda A. Resuscitation with Ringer's Lactate compared with normal saline for pediatric diabetic ketoacidosis. *Pediatr Emerg Care.* 2021 May 1;37(5):e236-242.

Rohrer TR, **Abuzzahab J**, Backeljauw P, Birkegård AC, Blair J, Dahlgren J, Júlíusson PB, Ostrow V, Pietropoli A, Polak M, Romano A, Ross J, Sävendahl L, Miller BS. Long-term effectiveness and safety of childhood growth hormone treatment in Noonan Syndrome. *Horm Res Paediatr*. 2021 Jan;13:1-16.

Roth CL, Perez FA, Whitlock KB, Elfers C, Yanovski JA, Shoemaker AH, **Abuzzahab MJ**. A phase 3 randomized clinical trial using a once-weekly glucagon-like peptide-1 receptor agonist in adolescents and young adults with hypothalamic obesity. *Diabetes Obes Metab*. 2021;23(2):363-373.

Abuzzahab MJ, Roth CL, Shoemaker AH. Hypothalamic Obesity: Prologue and Promise. *Horm Res Paediatr.* 2019;91(2):128–136.

Shoemaker A, Proietto J, **Abuzzahab MJ**, Markovic T, Malloy J, Kim DD. A randomized, placebo-controlled trial of beloranib for the treatment of hypothalamic injury-associated obesity.
Diabetes Obes Metab. 2017;19(8):1165-1170.

McCandless SE, Yanovski JA, Miller J, Fu C, Bird LM, Salehi P, Chan CL, Stafford D, **Abuzzahab MJ**, Viskochil D, Barlow SE, Angulo M, Myers SE, Whitman BY,

Styne D, Roof E, Dykens EM, Scheimann AO, Malloy J, Zhuang D, Taylor K, Hughes TE, Kim DD, Butler MG. Effects of MetAP2 inhibition on hyperphagia and body weight in Prader-Willi syndrome: A randomized, double-blind, placebo-controlled trial. *Diabetes Obes Metab*. 2017;19(12):1751-1761.

Fox CK, Kaizer AM, Rudser KD, Nathan BM, Gross AC, Sunni M, **Jennifer Abuzzahab M**, Schwartz BL, Kumar S, Petryk A, Billington CJ, Ryder JR, Kelly AS. Meal replacements followed by topiramate for the treatment of adolescent severe obesity: A pilot randomized controlled trial. *Obesity (Silver Spring)*. 2016;24(12):2553-2561.

Sunni M, Noble JA, Yu L, Mahamed Z, Lane JA, Dhunkal AM, Bellin MD, Nathan B, Kyllo J, **Abuzzahab MJ**, Gottlieb PA, Babu S, Armstrong T, Moran A. Predominance of DR3 in Somali children with type 1 diabetes in the twin cities, Minnesota. *Pediatr Diabetes*. 2017;18(2):136-142.

Nathan BM, Rudser KD, **Abuzzahab MJ**, Fox CK, Coombes BJ, Bomberg EM, Kelly AS. Predictors of weight-loss response with glucagon-like peptide-1 receptor agonist treatment among adolescents with severe obesity. *Clin Obes*. 2016;6(1): 73–78.

Sunni M, Farah M, Hardie C, Dhunkal AM, **Abuzzahab MJ**, Kyllo JH, Bellin MD, Nathan B, Moran A. Understanding cultural beliefs in families of Somali children with diabetes in the Twin Cities, Minnesota. *J Community Health*. 2015;40(4):827-33.

Kelly AS, Rudser KD, Nathan BM, Fox CK, Metzig AM, Coombes BJ, Fitch AK, Bomberg EM, **Abuzzahab MJ**. The effect of glucagon-like peptide-1 receptor agonist therapy on body mass index in adolescents with severe obesity: a randomized, placebo-controlled, clinical trial. *JAMA Pediatr*. 2013;167(4):355-60.

Kelly AS, Metzig AM, Rudser KD, Fitch AK, Fox CK, Nathan BM, Deering MM, Schwartz BL, **Abuzzahab MJ**, Gandrud LM, Moran A, Billington CJ, Schwarzenberg SJ. Exenatide as a weight-loss therapy in extreme pediatric obesity: a randomized, controlled pilot study. *Obesity (Silver Spring)*. 2012;20(2):364-70.

Smith EP, Specker B, Bachrach BE, Kimbro KS, Li XJ, Young MF, Fedarko NS, **Abuzzahab MJ**, Frank GR, Cohen RM, Lubahn DB, Korach KS. Impact on bone of an estrogen receptor-alpha gene loss of function mutation. *J Clin Endocrinol Metab*. 2008 Aug;93(8):3088-96.

Chernausek SD, **Abuzzahab MJ**, Kiess W, Osgood D, Schneider A, Smith R. IGF Resistance. The Role of the Type 1 IGF Receptor. In: Carel J-C, Kelly PA, Christen Y, eds. *Deciphering Growth (Research and Perspectives in Endocrine Interactions)*. Berlin, Germany: Springer; 2005:121-130.

Abuzzahab MJ, Schneider A, Goddard A, Grigorescu F, Lautier C, Keller E, Kiess W, Klammt J, Kratzsch J, Osgood D, Pfäffle R, Raile K, Seidel B, Smith RJ, Chernausek SD; Intrauterine Growth Retardation (IUGR) Study Group. IGF-I receptor mutations resulting in intrauterine and postnatal growth retardation. *N Engl J Med*. 2003;349(23):2211-22

Abuzzahab J, Gunlik J. Ear Nose and Throat Chapter. In: Baden, Kruse, et al, eds. *Alaska Community Health Aide/Practitioner Manual*. Indian Health Service; 1998:115-141.

Krevins JR, **Abuzzahab J**, Kruse DG. Respiratory Chapter. In: Baden, Kruse, et al, eds. *Alaska Community Health Aide/Practitioner Manual*. Indian Health Service; 1998:87-113.

ABSTRACTS/POSTERS/PRESENTATIONS

Dauber AN, **Abuzzahab MJ**, Chen JV, Kelepouris N, Fridman M, Shy M, Bunner S, Romano A, Bamba V. SAT-220 Real-world Evidence Of Treatment Patterns And Costs Of Turner Syndrome And Noonan Syndrome In The United States. Journal of the Endocrine Society. 2025 Oct;9(Supplement_1):bvaf149-1787.

McDonnell C, Hove H, Legare JM, Campeau PM, Hofman PL, Hoernschemeyer DG, de Bergua Domingo JM, **Abuzzahab MJ**, Mao M, Ballance I, Freiberg LC. OR36-05 Safety and Tolerability of Navepegritide Treatment in Children With Achondroplasia: 52-Week Results From the Pivotal ApproaCH Trial. Journal of the Endocrine Society. 2025 Oct;9(Supplement_1):bvaf149-1751.

Phillips SA, van Santen HM, Hamilton JK, Shoemaker AH, McCormack SE, **Abuzzahab MJ**, Wabitsch MJ, Dattani MT, Tanaka T, Scimia C, Yuan G. OR11-01 Efficacy And Safety Of Setmelanotide In Acquired Hypothalamic Obesity: Results From A Double-blind, Multicenter, Placebo-controlled, Randomized Phase 3 Trial. Journal of the Endocrine Society. 2025 Oct;9(Supplement_1):bvaf149-074.

Roth CL, Shoemaker AH, Ervin C, Norcross L, Fehnel S, Huber C, Scimia C, **Abuzzahab MJ**. 12418 Patient- And Caregiver-reported Experiences Of Hunger, Weight, And Energy In Acquired Hypothalamic Obesity Before And During Setmelanotide Treatment, *Journal of the Endocrine Society*, Volume 8, Issue Supplement_1, October-November 2024, bvae163.015.

Bergmann KR, **Abuzzahab MJ**, Perepelista V, Udeogu JE, Qiu L, Lammers SM, Watson D, Kharbanda A. A Quality Improvement Initiative to Improve Emergency Care for Children and Adolescents with Medium and High Risk Diabetic Ketoacidosis. Poster presented at: American Academy of Pediatrics; September 2024; Orlando, Florida.

Clark D, Mattice T, **Abuzzahab MJ,** Kharbanda A, Lammers SM, Nickel AJ, Bergmann KR. Hyperkalemia During Diabetic Ketoacidosis and the Association with Acute Kidney Injury. Poster presented at: American Academy of Pediatrics; September 2024; Orlando, Florida.

Langevin MA, Laquere R, Gossai N, **Abuzzahab MJ,** Maxa K, Hooke C. Why Am I Gaining Weight? Developing a Standardized Intervention for Insulin Resistance in Children with Acute Lymphoblastic Leukemia. Poster presented at: The Association of Pediatric Hematology/ Oncology Nurses; September 2024; Salk lake City, Utah.

Roth CL, Shoemaker A, Gottschalk M, Miller J, Guojun G, Malhotra S, Scimia C, **Abuzzahab MJ**. Weight reduction in patients with hypothalamic obesity treated with

Setmelanotide for 12 months. Poster presented at: European Congress of Endocrinology; May 2024; Stockholm, Sweden.

Savarirayan R, McDonnell C, Hoernschemeyer D, Hove H, Zarate Y, Bober M, Bacino C, Legare J, Högler W, Quattrin T, **Abuzzahab MJ**, Hofman P, White K, Ma N, Schnabel D, Sousa S, Fan X, Chakraborty M, Giwa A, Smith S, Volck B, Shu A. Significantly improved annual growth velocity with once-weekly TransCon CNP vs. placebo in children aged 2 to 10 years with Achondroplasia: The Accomplish phase 2, randomized, double-blind, placebo controlled, dose-escalation trial. Poster presented at: Annual Meeting of the Endocrine Society; June 2023; Chicago, IL.

Roth CL, Shoemaker AH, Gottschalk M, Miller J, Yuan G, Malhotra S, Chen E, Scimia C, **Abuzzahab MJ**. Efficacy and safety analysis of Setmelanotide as a novel treatment for Hypothalamic Obesity. Poster presented at: European Congress of Endocrinology; May 2023; Istanbul, Turkey.

Roth CL, Shoemaker AH, Gottschalk M, Miller J, Yuan G, Malhotra S, Scimia C, **Abuzzahab MJ**. Impact of Setmelanotide treatment on reducing hyperphagia in pediatric and adult patients with Hypothalamic Obesity. Poster presented at: European Congress of Endocrinology; May 2023; Istanbul, Turkey.

Roth CL, Shoemaker AH, Gottschalk M, Miller J, Yuan G, Malhotra S, Scimia C, **Abuzzahab MJ**. Impact of Setmelanotide treatment on reducing hyperphagia in pediatric and adult patients with Hypothalamic Obesity. Poster presented at: Pediatric Endocrine Society; May 2023; San Diego, CA.

Abuzzahab MJ. FRI066 Treatment History And Comorbidities Reported By Patients With Hypothalamic Obesity Treated With Setmelanotide In A Phase 2 Trial, *Journal of the Endocrine Society*, Volume 7, Issue Supplement_1, October-November 2023, bvad114.076.

Abuzzahab J, Angulo M, Bird L, Butler M, Cowen N, Gevers E, Goldstone A, Hirano P, Konczal L, Lah M, Verghese M, Corletto JM, Miller J, Obrynba K, Salehi P, Shaikh MG, Shoemaker A, Stevenson D, Viskochil D, Wilding J, Woloschak M, Yanovski J, Felner E. OR10-2 Hormonal and Cardiometabolic Changes Associated with Diazoxide Choline Extended-Release (DCCR) Tablets in Patients with Prader-Willi Syndrome, *Journal of the Endocrine Society*, Volume 6, Issue Supplement_1, November-December 2022, Pages A15–A16.

Roth CL, Shoemaker AH, Gottschalk M, Miller JL, Yuan G, Chen E, Scimia C, **Abuzzahab MJ**. Interim efficacy and safety analysis of Setmelanotide as a novel treatment for Hypothalamic Obesity. Poster presented at: The Annual Congress of European Childhood Obesity Group; November 2022; Vichy, France.

Roth CL, Shoemaker AH, Gottschalk M, Miller JL, Yuan G, Chen E, Scimia C, **Abuzzahab MJ**. Interim efficacy and safety analysis of Setmelanotide as a novel treatment for Hypothalamic Obesity. Poster presented at: The Obesity Society Obesity Week; November 2022; San Diego, CA.

Gevers E, Strong T, Miller J, Felner E, Goldstone T, Bridges N, Yanovski J, Bird L, Butler M, Obrynba K, Lah M, Shoemaker A, Mejia-Corletto J, Stevenson D, Wilding J, Kimonis V, **Abuzzahab J**, Konczal L, Mathew V, Cowen N, Woloschak M,

Bhatnar A. Comparison of hyperphagia and problem behaviors in participants with Prader-Willi Syndrome (PWS) receiving diazoxide choline extended-release (DCCR) with matched participants in PATH for PWS (PfPWS). Poster presented at: European Congress of Endocrinology; May 2022.

Gevers E, Miller J, Butler M, Bridges N, Goldstone T, Obrynba K, Salehi P, Felner E, Bird L, Shoemaker A, Konczal L, Lah M, Yanovski J, Angulo M, Mejia-Corletto J, Stevenson D, Wilding J, **Abuzzahab J**, Shaikh G, Viskochil D, Mathew V, Yen K, Woloschak M, Bhatnagar A. Long-term safety of diazoxide choline extended-release (DCCR) tablets in patients with prader-willi syndrome. Poster presented at: European Congress of Endocrinology; May 2022.

Abuzzahab MJ, Scimia C, Lekaditis S, Machus B, Kearns S, Roth CL. Safety and efficacy of Setmelanotide in patients with Hypothalamic Obesity: Phase 2 trial design. Poster presented at: Annual European Congress on Obesity; May 2022; Maastricht, Netherlands.

Júlíusson P, Dahlgren J, **Abuzzahab MJ**, Blair J, Pietropoli A, Roano A. Real-world safety data in children with Noonan syndrome treated with growth hormone: results from NordiNet®IOS and the Answer®Program. *Endocrine Abstracts.* 2019.

Angulo M, **Abuzzahab M**, Pietropoli A, Ostrow V, Tauber M. SAT-282 Outcomes in children treated with growth hormone for Prader-Willi Syndrome: Data from the Answer® Program and Nordinet® International Outcome Study (IOS). *J Endocr Soc*. 2019;3(Suppl 1):SAT-282.

Júlíusson P, Dahlgren J, **Abuzzahab MJ**, Blair J, Pietropoli A, Roano A. Real-world safety data in children with Noonan syndrome treated with growth hormone: results from NordiNet®IOS and the Answer®Program. Poster presented at: Annual Meeting of the European Society for Pediatric Endocrinology; September 2018; Athens, Greece.

Henson CJ, Barnes TL, Nickel AJ, **Abuzzahab MJ,** Kyllo J, Gandrud LM. Clinical Experience with the MiniMed 670G System in Children, Adolescents, and Young Adults with Type 1 Diabetes. *Diabetes* 1 July 2018; 67 (Supplement_1): 84–LB.

Skrypak M, Brown A, Pape-Blabolil J, Bendelsmith C, Patel, S, Patterson R, **Abuzzahab MJ**, Ingram, K, Linabery, A, Bendel, A. EPID-13: Isolated Pituitary Stalk Thickening (ISPT) in Children: Natural History and Predictors of Neoplastic Disease. *Neuro Oncol.* 2018;20(Suppl 2).

Romano AA, Konrad D, Chudecka AI, Pedersen BT, **Abuzzahab MJ**, Dahlgren J. Treatment outcomes in children with Noonan Syndrome – an analysis NORDINET® IOS and ANSWER Program. Poster presented at: International Meeting of Pediatric Endocrinology; September 2017; Washington, D.C.

Butler MG, McCandless SE, Roof E, Dykens EM, Fu C, Stafford DE, Angulo M, Myers S, Bird LM, Salehi P, Barlow SE, **Abuzzahab MJ**, Yanovski JA, Viskochil DH, Chan CL, Styne DM, Malloy J, Zhuang D, Kim D. Weight loss and improvement in hyperphagia-related behavior: results from bestPWS, a phase 3, randomized, placebo-controlled, clinical trial of Beloranib in Prader-Willi Syndrome. Oral

presentation collaboration at: Annual Meeting of the Endocrine Society; April 2016; Boston, MA.

Abuzzahab MJ, Myers S, Angulo M, Malloy J, Zhuang D, Taylor K, Stafford DE. Weight loss and improvement in body composition: results from bestPWS, a phase 3 randomized, placebo-controlled clinical trial of Beloranib in Patients with Prader-Willi Syndrome. Poster presentation at: Annual Meeting of the Endocrine Society; April 2016; Boston, MA.

Salehi P, **Abuzzahab MJ**, Bird L, Walsh B, Zhuang D, Kim D, Yanovski JA. Improvement in lipids and markers of cardiometabolic risk: results from bestPWS, a phase 3 randomized, placebo-controlled clinical trial of Beloranib in Patients with Prader-Willi Syndrome. Poster presentation at: Annual Meeting of the Endocrine Society; April 2016; Boston, MA.

Abuzzahab MJ, Salehi P, Styne DM, Chan CL, Kim T, Zhuang D, Kreher N, Angulo M. Improvement in hyperphagia and weight loss not influenced by growth hormone: results from bestPWS, a phase 3, randomized, placebo-controlled clinical trial of Beloranib in patients with Prader-Willi Syndrome. Poster presentation at: Annual Meeting of the Endocrine Society; April 2016, Boston, MA.

Salehi P, **Abuzzahab MJ**, Bird LM, Walsh B, Zhuang D, Kim D, Yanovski JA. Improvement in Lipids and Markers of Cardiometabolic Risk: Results from bestPWS, a Phase 3, Randomized, Placebo-Controlled, Clinical Trial of Beloranib in Prader-Willi Syndrome. Poster presentation at: Annual International Congress on Obesity; May 2016; Vancouver, BC.

Abuzzahab MJ, Myers S, Angulo M, Malloy J, Zhuang D, Taylor K, Stafford DE. Weight loss and improvement in body composition: results from bestPWS, a phase 3, randomized, placebo-controlled, Clinical Trial of Beloranib in Prader-Willi Syndrome. Poster presentation at: Annual International Congress on Obesity; May 2016; Vancouver, BC.

Hypothalamic obesity. Annual Pediatric Endocrinology Symposium. December 2015. Mineola, NY.

Cohen P, Counts D, **Abuzzahab MJ**, Gut R, Germak J. Responses to growth hormone treatment in pediatric patients with Prader-Willi Syndrome: Analysis of 3-year data from the ANSWER Program. Poster presentation at: Pediatric Academic Society Annual Meeting; April 2012; Boston, MA.

Abuzzahab MJ, Daniels M, Kelly AS, Miller B, Kyllo J. Effects of exenatide on hypothalamic obesity. Platform session at: Pediatric Academic Society Annual Meeting; April 2012; Boston, MA.

Kelly AS, Rudser KD, Nathan BM, Fox CK, Metzig AM, Coombes BJ, Fitch AK, Bomberg EM, **Abuzzahab MJ**. The effect of glucagon like peptide-1 receptor agonist

therapy on body mass index in adolescents with severe obesity. Poster presentation at: Obesity Society Annual Meeting; September 2012; San Antonio, TX.

Kelly AS, Metzig AM, Rudser KD, Fitch AK, Fox CK, Nathan BM, Steinberger J, Deering MM, Schwartz BL, **Abuzzahab MJ**, Gandrud LM, Moran A, Billington CJ, Schwarenberg SJ. Exenatide as a weight-loss therapy in extremely obese youth without diabetes. Poster presentation at: ADA Scientific Sessions; June 2011; San Diego, CA. President's Poster Selection.

Arcilla LM, Polgreen LE, Miller BS, Girard C, **Abuzzahab MJ**. IGF-1 generation testing predicts response to recombinant human growth hormone therapy. Poster presentation at: Pediatric Academic Societies & Asian Society for Pediatric Research Joint Meeting; May 2008; Honolulu, HI.

Osgood D, **Abuzzahab MJ**, Chernausek SD, Grigorescu F, Keller E, Kiess W, Klammt J, Kratsch J, Lautier C, Pfaffle R, Raile K, Schneider A, Seidel B, Smith RJ. Heterozygous mutations in the human IGF-1 receptor result in decreased IGF-1 sensitivity. Poster Presentation at: Endocrine Society Meeting; June 2004; New Orleans, LA.

Osgood D, **Abuzzahab MJ**, Banach W, Smith RJ, Chernausek SD. Compound heterozygosity for human IGF-1 receptor mutations in a child as a cause for decreased IGF-1 receptor responsiveness, and growth retardation. Poster presentation at: Growth Hormone Research Society, 1st Joint Symposium; 2002.

Abuzzahab MJ, Goddard A, Gricorescu F, Lautier C, Smith RJ, Chernausek SD. Human IGF-1 receptor mutations associated with intrauterine and post-natal growth retardation. Oral Presentation at: Endocrine Society Meeting; June 2000; Toronto, ON.

Abuzzahab MJ, Frank G, Goddard A, Gricorescu F, Kaplowitz PB, Lautier C, Smith RJ, Chernausek SD. The role of the IGF-1 receptor in intrauterine growth retardation. Poster presentation at: Annual National Cooperative Growth Study Investigator's Meeting; 1999.

.